Planet Biotechnology Incorporated

Company Information
Address 25571 CLAWITER RD
HAYWARD , CA, 94545-2740


Information

DUNS: 052917593

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A mucosally targeted MERS-CoV vaccine produced in plants

    Amount: $236,488.00

    DESCRIPTION provided by applicant Middle East Respiratory Syndrome MERS coronavirus MERS CoV causes severe acute respiratory illness with a high fatality rate among reported cases MERS was fi ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. A novel anti-gonorrhea immunotherapeutic

    Amount: $242,093.00

    Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  3. A MERS-CoV Receptor Decoy

    Amount: $1,575,242.00

    DESCRIPTION provided by applicant Middle East respiratory syndrome coronavirus MERS CoV is a newly emerging human health threat with a case fatality rate MERS CoV uses dipeptidyl peptidase ...

    SBIRPhase II2015Department of Health and Human Services
  4. Lab research for the development of anti-diphetheria antibodies in humans

    Amount: $150,000.00

    Diphtheria is an acute bacterial disease with a considerable case fatality rate caused by toxigenic Corynebacteria. Diphtheria toxin (DT) is the major virulence factor for these organisms. DT is synth ...

    SBIRPhase I2014Department of Health and Human Services
  5. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    Amount: $276,767.00

    DESCRIPTION (provided by applicant): Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism by which therapeutic monoclonal antibodies (mAbs) kill tumor cells. However, killing by ...

    SBIRPhase I2013Department of Health and Human Services
  6. An immunoadhesin for treatment of hypercholesterolemia

    Amount: $282,629.00

    DESCRIPTION (provided by applicant): In this project we propose producing, and testing in vivo, a recombinant protein that should sustainably reduce plasma low-density lipoprotein cholesterol (LDL-C). ...

    SBIRPhase I2012Department of Health and Human Services
  7. Plant-Made Nanobodies for Botulism Treatment

    Amount: $236,847.00

    DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective therapeutic that can reverse the paralytic symptoms ...

    SBIRPhase I2011Department of Health and Human Services
  8. Novel Therapy for Pulmonary Anthrax

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Planet Biotechnology Inc. (PBI) is developing a therapeutic recombinant protein, PBI-220, that neutralizes anthrax toxin in vitro and protects against inhalationa ...

    SBIRPhase II2010Department of Health and Human Services
  9. Maximizing Expression of Immunoglobulins in Plants

    Amount: $797,961.00

    DESCRIPTION (provided by applicant): Planet Biotechnology Inc. (PBI) has pioneered methods for the production of functional therapeutic antibodies and immunoadhesins in transgenic tobacco. For rea ...

    SBIRPhase II2010Department of Health and Human Services
  10. An Immunoadhesin Therapy for Gastrointestinal Anthrax

    Amount: $159,096.00

    DESCRIPTION (provided by applicant): The development of anthrax countermeasures has focused almost exclusively on the perceived threat of inhalational anthrax. However, preparing a sufficiently fine p ...

    SBIRPhase I2009Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government